Alzheimer's drug trial halted early: what happened?
NCT ID NCT05478031
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called REM0046127 in people with mild to moderate Alzheimer's disease. The goal was to see if it was safe and how it affected brain chemicals and brain wave activity. The trial was stopped early and included only 14 participants instead of the planned 30 to 60. Participants took either a high dose, low dose, or placebo for 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BRC Amsterdam
Amsterdam, Amsterdam, 1081, Netherlands
-
FISEVI Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Fundacion ACE
Barcelona, 08029, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of dementia cases reshape how we care for patients?
- PET scans probe link between brain inflammation and Alzheimer's damage
- Can sound waves soothe Dementia's emotional turmoil?
- Can a Low-Dose immune calmer slow Alzheimer's decline?
- A stumble before memory slips? study tests if falls predict Alzheimer's
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?